Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 20/20 | 1.00 |
| ▸ | F2 | P00734 | 13/20 | 1.00 |
| ▸ | F10 | P00742 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2802124 | 1.00 | F7 (1.00) | F7F2F10 | |
| SCHEMBL4231819 | 0.91 | F7 (0.84) | F7F2F10 | |
| SCHEMBL4231809 | 0.91 | F7 (0.84) | F7F2F10 | |
| SCHEMBL4231817 | 0.91 | F7 (0.84) | F7F2F10 | |
| SCHEMBL3863203 | 0.91 | F7 (0.84) | F7F2F10 | |
| SCHEMBL4958022 | 0.86 | F7 (0.75) | F7F2F10 | |
| SCHEMBL4958055 | 0.86 | F7 (0.75) | F7F2F10 | |
| SCHEMBL13993084 | 0.86 | F7 (0.75) | F7F2F10 | |
| SCHEMBL13936352 | 0.85 | F7 (1.00) | F7F2F10 | |
| SCHEMBL235788 | 0.85 | F7 (1.00) | F7F2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656158-B1 | LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDES | NOVO NORDISK HEALTHCARE AG (CH) | 2016-03-09 | — | — | EP | claimed |
| US-20130084274-A1 | Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides | NOVO NORDISK HEALTH CARE AG (CH) | 2013-04-04 | — | — | US | claimed |
| US-8318904-B2 | Liquid, aqueous pharmaceutical compositions of factor VII polypeptides | NOVO NORDISK HEALTH CARE AG (CH) | 2012-11-27 | — | — | US | claimed |
| US-20120003206-A1 | LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITIONS OF FACTOR VII POLYPEPTIDES | NOVO NORDISK HEALTHCARE A/G (CH) | 2012-01-05 | — | — | US | claimed |
| US-7732405-B2 | Liquid, aqueous pharmaceutical compositions of factor VII polypeptides | NOVO NORDISK HEALTH CARE AG (CH) | 2010-06-08 | — | — | US | claimed |
| US-20060205648-A1 | Liquid, aqueous pharmaceutical compositions of factor VII polypeptides | NOVO NORDISK HEALTHCARE A/G (CH) | 2006-09-14 | — | — | US | claimed |
| EP-1656158-B1 | LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDES | NOVO NORDISK HEALTHCARE AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| EP-1656158-B1 | LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDES | NOVO NORDISK HEALTHCARE AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| US-20150273027-A1 | LIQUID PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDE | NOVO NORDISK HEALTHCARE AG (CH) | 2015-10-01 | — | — | US | disclosed |
| US-20130084274-A1 | Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides | NOVO NORDISK HEALTH CARE AG (CH) | 2013-04-04 | — | — | US | disclosed |
| US-8318904-B2 | Liquid, aqueous pharmaceutical compositions of factor VII polypeptides | NOVO NORDISK HEALTH CARE AG (CH) | 2012-11-27 | — | — | US | disclosed |
| US-20120003206-A1 | LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITIONS OF FACTOR VII POLYPEPTIDES | NOVO NORDISK HEALTHCARE A/G (CH) | 2012-01-05 | — | — | US | disclosed |
| US-8026214-B2 | Liquid, aqueous pharmaceutical compositions of factor VII polypeptides | NOVO NORDISK HEALTH CARE AG (CH) | 2011-09-27 | — | — | US | disclosed |
| US-20100056453-A1 | Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides | NOVO NORDISK HEALTHCARE A/G (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056453-A1 | Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides | NOVO NORDISK HEALTHCARE A/G (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20090111751-A1 | Method of Removing a Non-Metallic Protein Inhibitor From a Liquid Pharmaceutical Preparation | NOVO NORDISK HEALTH CARE AG (CH) | 2009-04-30 | — | — | US | disclosed |
| WO-2006128497-A1 | PHARMACEUTICAL FORMULATION OF FACTOR XI | NOVO NORDISK A/S (DK) | 2006-12-07 | — | — | WO | disclosed |
| US-20060205648-A1 | Liquid, aqueous pharmaceutical compositions of factor VII polypeptides | NOVO NORDISK HEALTHCARE A/G (CH) | 2006-09-14 | — | — | US | disclosed |
| EP-1656158-A2 | LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDES | Novo Nordisk Health Care AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005016365-A2 | LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDES | NOVO NORDISK HEALTH CARE AG (CH) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150273027-A1 | LIQUID PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDE | F7, F8, F9 | F7 1/4885F2 7/4885F10 11/4885 |
| US-20060205648-A1 | Liquid, aqueous pharmaceutical compositions of factor VII polypeptides | F7, F5, F12 | F7 1/4885F2 44/4885F10 16/4885 |
| US-20120003206-A1 | LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITIONS OF FACTOR VII POLYPEPTIDES | F7, F5, F12 | F7 1/4885F2 40/4885F10 15/4885 |
| US-20100056453-A1 | Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides | F7, F5, F12 | F7 1/4885F2 40/4885F10 15/4885 |
| US-20130084274-A1 | Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides | F7, F5, F12 | F7 1/4885F2 40/4885F10 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.